These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3178437)

  • 21. Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound.
    Rao MS; Dwivedi RS; Subbarao V; Reddy JK
    Br J Cancer; 1988 Jul; 58(1):46-51. PubMed ID: 2901849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Amino acid derivatives of 2-(p-chlorophenoxy)-2-methylpropionic acid as compounds with potential antilipemic agents. II. Preparation of methyl esters of N-[2-(p-chlorophenoxy)-2-methylpropionyl] amino acids].
    Kwapiszewski W; Borkowski L
    Acta Pol Pharm; 1987; 44(2):121-31. PubMed ID: 3434313
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia.
    Dick TB; Marples J; Ledermann HM; Whittington J
    Curr Med Res Opin; 1981; 7(8):489-502. PubMed ID: 7030635
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of ciprofibrate and 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate (POCA) on the distribution of carnitine and CoA and their acyl-esters and on enzyme activities in rats. Relation between hepatic carnitine concentration and carnitine acetyltransferase activity.
    Bhuiyan AK; Bartlett K; Sherratt HS; Agius L
    Biochem J; 1988 Jul; 253(2):337-43. PubMed ID: 3178716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative bioavailability of etofibrate. A comparison of an acute and a new sustained release formulation.
    Johnson KI; Hoppe HJ; Schatton W
    Arzneimittelforschung; 1984; 34(12):1785-7. PubMed ID: 6543315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Species differences in the hepatic response to a potent peroxisome proliferator.
    Makowska JM; Bonner FW; Goldfarb PS; Gibson GG
    Biochem Soc Trans; 1989 Dec; 17(6):1072-3. PubMed ID: 2628085
    [No Abstract]   [Full Text] [Related]  

  • 27. Concentration of clofibric acid in blood after the administration of delayed-release form of etofibrate.
    Vazquez Lopez F; Armijo Castro F; Pire Solis I; Gutierrez Fuentes JA
    Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):31-5. PubMed ID: 3557726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastric morphological changes including carcinoid tumors in animals treated with a potent hypolipidemic agent, ciprofibrate.
    Spencer AJ; Barbolt TA; Henry DC; Eason CT; Sauerschell RJ; Bonner FW
    Toxicol Pathol; 1989; 17(1 Pt 1):7-15. PubMed ID: 2501865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Rhabdomyolysis under treatment by ciprofibrate in the nephrotic syndrome].
    Baglin A; Lasserre N; Prinseau J; Lebas M
    Therapie; 1987; 42(2):247-8. PubMed ID: 3617003
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pharmacokinetics of hypolipedemic agents. 9. The question of biliary excretion of the hypolipidemic agent ciprofibrate (1) (2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-2-methylpropionic acid].
    Oelschläger H; Rothley D; Schröder D; Scherm S
    Arch Pharm (Weinheim); 1992 Nov; 325(11):701-4. PubMed ID: 1485836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of the peroxisome proliferator ciprofibrate on hepatic DNA synthesis and hepatic composition following partial hepatectomy in rats.
    Srinivasan SR; Chow CK; Glauert HP
    Toxicology; 1990 Jun; 62(3):321-32. PubMed ID: 2389247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peroxisome proliferator-binding protein: identification and partial characterization of nafenopin-, clofibric acid-, and ciprofibrate-binding proteins from rat liver.
    Lalwani ND; Alvares K; Reddy MK; Reddy MN; Parikh I; Reddy JK
    Proc Natl Acad Sci U S A; 1987 Aug; 84(15):5242-6. PubMed ID: 3474650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of fibric acid derivatives on biliary lipid composition.
    Palmer RH
    Am J Med; 1987 Nov; 83(5B):37-43. PubMed ID: 3318452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of various fibrates on serum alkaline phosphatase activity.
    Ganotakis E; Tsimihodimos V; Bairaktari E; Rizos E; Athyros V; Seferiades C; Elisaf M
    Atherosclerosis; 2002 Nov; 165(1):187-8. PubMed ID: 12208487
    [No Abstract]   [Full Text] [Related]  

  • 35. The enantiomeric resolution of ciprofibrate and related compounds by HPLC using chiral stationary phases.
    Anderson NH; Johnston D; Vojvodic PR
    J Pharm Biomed Anal; 1992 Jul; 10(7):501-5. PubMed ID: 1420475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacology and mechanism of action of etofibrate].
    Schatton W
    Med Welt; 1982 Sep; 33(38):1310-4. PubMed ID: 6752630
    [No Abstract]   [Full Text] [Related]  

  • 37. Induction and origin of hepatocytes in rat pancreas.
    Reddy JK; Rao MS; Qureshi SA; Reddy MK; Scarpelli DG; Lalwani ND
    J Cell Biol; 1984 Jun; 98(6):2082-90. PubMed ID: 6202703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ciprofibrate and lipid profile.
    McLeod AJ; Warren RJ; Armitage M
    Lancet; 1994 Oct; 344(8927):955. PubMed ID: 7934365
    [No Abstract]   [Full Text] [Related]  

  • 39. In vivo distribution of a carcinogenic hepatic peroxisome proliferator: whole-body autoradiography of [14C]ciprofibrate in the mouse.
    Waddell WJ; Marlowe C; Rao MS; Reddy JK
    Carcinogenesis; 1989 Jan; 10(1):221-3. PubMed ID: 2910527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of peroxisome proliferation in rainbow trout exposed to ciprofibrate.
    Yang JH; Kostecki PT; Calabrese EJ; Baldwin LA
    Toxicol Appl Pharmacol; 1990 Jul; 104(3):476-82. PubMed ID: 2385837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.